| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(10 years from now) | |
Tagrisso is owned by Astrazeneca.
Tagrisso contains Osimertinib Mesylate.
Tagrisso has a total of 4 drug patents out of which 0 drug patents have expired.
Tagrisso was authorised for market use on 13 November, 2015.
Tagrisso is available in tablet;oral dosage forms.
Tagrisso can be used as adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations, treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations.
Drug patent challenges can be filed against Tagrisso from 14 November, 2019.
The generics of Tagrisso are possible to be released after 02 January, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
| Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
| New Indication(I-774) | Apr 18, 2021 |
| New Indication(I-853) | Dec 18, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after t...
Dosage: TABLET;ORAL
TAGRISSO family patents
